Eli Lilly’s stock soared by as much as 17% after positive phase-three trial data was released for orforglipron, a GLP-1 weight-loss pill. The results showed that the once-daily pill reduced patients’ weight by an average of 16 pounds and lowered their A1C levels by an average of 1.3-1.6%. This news gives Eli Lilly the green light to file for regulatory approval.
The pill form is comparable to injectable GLP-1 drugs, like Novo Nordisk’s Ozempic, which are also used for weight loss and diabetes treatment. The positive data could expand access to patients who fear needles and lower costs due to more efficient manufacturing processes.
Analysts at JPMorgan described the trial data as exceptional, with minimal side effects reported. They predict a steep ramp-up in sales for orforglipron upon its launch and an increase in Eli Lilly’s overall sales estimates. With shares now positive for the year, this news marks a significant milestone for Eli Lilly and its potential obesity treatment.
Source: https://www.businessinsider.com/eli-lilly-stock-price-soars-weight-loss-pill-rivals-ozempic-2025-4